Loading
Farletuzumab-exatecan is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials, aimed at Folate receptor alpha.
Farletuzumab-exatecan (SYS6041) is an antibody-drug conjugate developed by CSPC Megalith Biopharmaceutical. Its target is Folate receptor alpha (the sponsor names Folate receptor alpha (FRα)). The sponsor states: SYS6041 (farletuzumab-exatecan) is an antibody-drug conjugate targeting human folate receptor alpha with a topoisomerase I inhibitor payload, given by intravenous injection on day 1 of each three-week cycle. ClinicalTrials.gov describes the intervention as: Farletuzumab-exatecan antibody-drug conjugate targeting human FRα. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07744763, plans to enrol 260 participants with primary completion expected 2027-03-28. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
SYS6041 (farletuzumab-exatecan) is an antibody-drug conjugate targeting human folate receptor alpha with a topoisomerase I inhibitor payload, given by intravenous injection on day 1 of each three-week cycle. Connects to Folate receptor alpha.
1.Farletuzumab-exatecan's antibody arm binds Folate receptor alpha on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Farletuzumab-exatecan" OR ABSTRACT:"Farletuzumab-exatecan" OR TITLE:"SYS6041" OR ABSTRACT:"SYS6041") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Farletuzumab-exatecan, not a curated reading list.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.